Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 20/20 Biolabs, Inc.AIDX · Entity 8097 | Director · Chief Executive Officer · 10% owner | March 03, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
20/20 Biolabs, Inc.
Report date March 03, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2036-03-03 | Direct | 352,936 |
Reported balance
After 2026-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 352,936 · Balance 352,936 F1: On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 22:48 UTC | 20/20 Biolabs, Inc. AIDX · Entity 8097 | GrantStock Option · Derivative | 352,936 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001213900-26-023758 · ownership.xml · derivative · entry 1 Cohen Jonathan M · CIK 0002111543 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,936 Underlying: Common Stock · 352,936 shares Expires 2036-03-03 F1 · security: On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer. F1 · derivative.exercise_date: On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.